Bosutinib: Interim Phase I/II data

Interim data from 70 evaluable patients with Philadelphia chromosome-positive (Ph+) chronic phase CML who had failed prior Gleevec imatinib therapy and were resistant or intolerant to Sprycel dasatinib or resistant to Tasigna nilotinib in the ongoing Phase I/II Study 200 trial showed that 26% of patients treated with once-daily oral bosutinib achieved a major cytogenetic response at week 24, including 13% with a CCyR. Adverse events led to treatment discontinuations in 27% of Sprycel-intolerant patients, 14% of Sprycel-resistant patients and 11% of Tasigna-resistant patients. Data were presented at the American Society of Hematology meeting in Orlando. ...